Skip to main content
Erschienen in:

01.06.2019 | Clinical study

Semaglutide: no increased risk of cardiovascular events

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Semaglutide does not appear to increase the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM), according to findings of the Novo Nordisk-funded PIONEER 6 trial published in the New England Journal of Medicine. …
Metadaten
Titel
Semaglutide: no increased risk of cardiovascular events
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-63556-5